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Abstract
Background: Adverse outcomes have recently been linked to elevated red cell distribution width
(RDW) in heart failure. Our study sought to validate the prognostic value of RDW in heart failure
and to explore the potential mechanisms underlying this association.
Methods and Results: Data from the Study of Anemia in a Heart Failure Population
(STAMINA-HFP) registry, a prospective, multicenter cohort of ambulatory patients with heart
failure supported multivariable modeling to assess relationships between RDW and outcomes. The
association between RDW and iron metabolism, inflammation, and neurohormonal activation was
studied in a separate cohort of heart failure patients from the United Investigators to Evaluate
Heart Failure (UNITE-HF) Biomarker registry. RDW was independently predictive of outcome
(for each 1% increase in RDW, hazard ratio for mortality 1.06, 95% CI 1.01-1.12; hazard ratio for
hospitalization or mortality 1.06; 95% CI 1.02-1.10) after adjustment for other covariates.
Increasing RDW correlated with decreasing hemoglobin, increasing interleukin-6, and impaired
iron mobilization.
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Conclusions: Our results confirm previous observations that RDW is a strong, independent
predictor of adverse outcome in chronic heart failure and suggest elevated RDW may indicate
inflammatory stress and impaired iron mobilization. These findings encourage further research
into the relationship between heart failure and the hematologic system.
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Identification of novel markers of prognosis may improve clinical decision making, and may
also provide insights into the pathophysiology of complex clinical syndromes such as heart
failure. A large body of recent literature has characterized the strong relationship between
anemia and adverse outcomes in heart failure.1-7 These data have led to the hypothesis that
anemia may be a therapeutic target in heart failure, and have resulted in increased interest in
pathophysiologic links between heart failure and the hematologic system.8,9
We recently reported the strong association of increasing red cell distribution width (RDW),
a measure of the variability in size of circulating red cells, with adverse outcomes in 2 large
chronic heart failure cohorts.10 This association was consistently independent of
hemoglobin, and persisted as 1 of the strongest overall predictors of prognosis despite
adjustment for a broad array of clinical and laboratory variables. Subsequently, RDW has
also been shown to correlate with adverse outcomes in populations of patients with
established coronary disease,11 those referred for coronary angiography12 in middle-aged
and older adults,13 and in the general population.14 Before novel prognostic biomarkers such
as RDW can be incorporated into clinical practice, they require confirmation in multiple
datasets evaluating broad populations with the disease of interest to definitively establish
validity and generalizability. Additionally, understanding the pathophysiology underlying
the association of novel biomarkers with outcomes provides support for the biologic
plausibility of the biomarker, and may provide additional insight into fundamental
mechanisms of disease. Using data from 2 prospective, multicenter registries, we sought to
validate our previous observations on the association between RDW and prognosis and to




STAMINA-HFP Registry—The Study of Anemia in a Heart Failure Population
(STAMINA-HFP) registry was a multicenter, prospective, observational study of a
randomly selected sample of ambulatory patients with heart failure in the United States,
including both academic specialty sites and community practices with an interest in heart
failure.15 The heart failure specialty sites were part of the United Investigators to Evaluate
Heart Failure (UNITE-HF), an investigative research group of heart failure specialists
created to conduct registry and other types of clinical studies in patients with this
syndrome.16 Patients were eligible for participation if they were 18 years of age or older,
had symptomatic heart failure, and were willing and able to complete quarterly telephone
interviews and other study assessments. Eligibility was not dependent on a specific left
ventricular ejection fraction or the presence of anemia. Both new and return outpatients with
heart failure were candidates for study enrollment. Patients were randomly selected for
participation using an algorithm to select every nth patient with heart failure on the clinic
schedule as a potential candidate for enrollment.
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Detailed demographic, clinical, and laboratory data were collected on all patients at the time
of enrollment. Hemoglobin was determined at enrollment and during follow-up clinic visits
by finger-stick (HemoCue). Red cell distribution width was determined by automated
complete blood cell counts from a baseline blood sample processed at each site’s clinical
laboratory or the most recent results available in patients lacking a baseline sample. These
values were available within 30 days of enrollment in 96.4% of the patients. Follow-up
clinical data were collected naturalistically from medical encounters related to usual care or
as indicated by medical need.
UNITE-HF Biomarker Registry—A separate prospective multicenter registry, the
UNITE-HF Biomarker registry was conducted in parallel to STAMINA-HFP, with the goal
of evaluating biomarkers and clinical correlates of anemia in patients with heart failure. This
study enrolled a convenience sample of outpatients with symptomatic heart failure recruited
by a subgroup of the UNITE-HF investigators. Enrollment criteria were the same for both
registries, but each registry recruited a distinct cohort of patients. Patients in the UNITE-HF
Biomarker registry had a baseline visit to collect detailed information concerning their
medical history and heart failure state. Patient follow-up was obtained through routine clinic
visits and yearly contact (for at least 2 years) to determine vital status and occurrence of
hospitalization.
Venous samples of whole blood, plasma, and serum were collected in the UNITE-HF
Biomarker registry at the baseline clinic visit that occurred during regular daytime hours.
Plasma was collected from whole blood processed in prechilled EDTA tubes by cold
centrifugation (4°C) at 2000g within 20 minutes of collection. Plasma and serum samples
were stored at −70°C until they could be batch shipped under dry ice to the UNITE-HF
Biomarker Core Laboratory at the University of North Carolina at Chapel Hill. A portion of
the patient’s whole blood (collected in an EDTAVacutainer tube) and serum were stored at
4°C and sent by overnight mail to the core laboratory. Subsequently, automated complete
blood counts, routine chemistries, and measurements of iron status were determined on these
samples by standard methods in the clinical laboratory of the University of North Carolina
Hospitals. Serum levels of tumor necrosis factor alpha, interleukin (IL)-1 beta, and IL-6
were measured by high-sensitivity enzyme-linked immunosorbent assay and serum
erythropoietin and plasma levels of endothelin-1 were measured by standard enzyme linked
immunosorbent assay methods. All assays were conducted using commercially available kits
(Quantikine, R&D Systems, Minneapolis, MN). The minimum detectable concentration of
tumor necrosis factor alpha was <4.4 pg/mL, whereas for IL-1 beta and IL-6 it was <1 pg/
mL. Assays were performed by technicians unaware of patient clinical characteristics and
outcome.
Both protocols were approved by the relevant local institutional review boards, and all
enrolled patients provided written, informed consent.
Statistical Analysis
STAMINA-HFP Registry—The primary study analysis used Cox proportional hazards
models, univariable and multivariable, to evaluate the association between RDW (as a
continuous variable) and the clinical end points of all-cause mortality and all-cause
hospitalization or mortality. Variables considered for inclusion in the multivariable models
as potential confounders of the relationship of RDW to study outcomes were: gender; race;
age; New York Heart Association functional class; estimated glomerular filtration rate;
history of diabetes, hypertension, atrial fibrillation or flutter; left ventricular ejection
fraction; ischemic heart disease; systolic blood pressure; diastolic blood pressure; heart rate;
pulse pressure; edema by physical exam; or current smoking and current medications
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(angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, β-blocker, any
diuretic, loop diuretic). Each was assessed univariably with the study outcomes, and those
with P < .05 were included in multivariable models, through which adjusted hazard ratios
for RDW were determined. Because of high levels of missing values, duration of heart
failure, body mass index, and blood urea nitrogen were also considered for subsequent
inclusion to supplemental multivariable models where applicable. The relationships between
the variable of interest (RDW) and the outcomes were expressed using hazards ratios (HR)
and their 95% confidence intervals (CI), and the relative strength of association of each
predictor was assessed based on the chi-square statistic with 1 degree of freedom in the
adjusted model. A test of the proportional hazard assumption for the RDW effect was
conducted through a test of the interaction of RDW with follow-up time. Departure from
linearity for the RDW effect was assessed through the joint testing of cubic and quadratic
polynomial terms.
C-statistics were computed to reflect a particular model’s degree of discrimination for
whether a patient has an event or not. Such models were formulated with and without RDW
as a predictor, and the corresponding c-statistics indicate the additional discrimination
provided by inclusion of RDW in the model.
For descriptive purposes, patients in the study cohort from the STAMINA-HFP registry (n =
1016) were grouped into ranges of RDW based on the lowest quartile of RDW, middle 50%
range of RDW, and the highest quartile of RDW. The distribution of RDW values was also
characterized based on the normal range defined as ≤15%. Kaplan Meier methods were used
to examine unadjusted event rates at 1 year, and the log-rank test assessed differences
among event rates across the RDW ranges and P values for differences among these patient
groups. Differences in baseline characteristics across these same groups were determined
using analysis of variance and chi-square tests, as appropriate.
UNITE-HF Biomarker Registry—Spearman correlation analysis examined the general
relationships between RDW and biomarkers of inflammation, iron metabolism, and
neurohormonal activation. For descriptive purposes, patients in the UNITE-HF Biomarker
registry were also grouped based on the same cut points of RDW used in the STAMINA-
HFP registry. Biomarkers of interest were evaluated across these 2 patient groups by trend
testing using Spearman correlation (with results reported through medians and first and third
quartiles). Recognizing that selection of the RDW grouping cut points above was arbitrary,
additional descriptive analyses were performed with patients divided into normal versus
abnormal RDW groups with the normal range for RDW defined as ≤15%, as in the
STAMINA-HFP registry. Differences between these groups were assessed by t-tests and
chi-square tests as appropriate.
Data on various inflammatory cytokines and endothelin-1 were available in subsets of the
cohort with RDW. To help address the potential of bias in the selection of these patients,
baseline characteristics in the IL-6 subset were compared with the overall cohort with RDW.
Characteristics that differed were included in multiple linear regression modeling of the
relationship of IL-6 to RDW.
General Considerations
Results summarizing the baseline characteristics of patients in both registries are reported as
means ± standard deviations (SD), medians, first and third quartiles (Q1 and Q3,
respectively), or percentages as appropriate. In this report, anemia was defined using the
World Health Organization criteria of baseline hemoglobin <13 g/dL for men and <12 g/dL
for women.17 A P value <.05 was considered statistically significant in all analyses.
Analyses were conducted with SAS 9.1 (SAS Institute, Inc, Cary, NC).
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Results
STAMINA-HFP Registry
Baseline Characteristics—A total of 1016 (94%) of 1082 subjects in the STAMINA-
HFP registry had RDW values available and formed the population for this analysis. This
cohort was older (37% age ≥70), male, and Caucasian (Table 1). Thirty-four percent of
patients had anemia based on World Health Organization criteria. For this registry cohort,
the mean RDW was 14.7 ± 2.5%. The median RDW in the cohort was 14.2% (Q1-Q3
13.4-15.5%), and 31% of patients had an abnormal value (> 15%). RDW was modestly
correlated with hemoglobin (Spearman r = −0.24, P < .001). In general, patients with
elevated RDW were older, more likely to be African American, and tended to have more
severe heart failure and a greater burden of comorbidity, as shown in Table 1.
RDW and Clinical Outcomes—Data on outcomes were available in 1012 patients in the
STAMINA-HFP study cohort. The mean duration of follow-up of these patients was 1.0 ±
0.3 years. There were 77 deaths during follow-up, and the crude 1-year mortality rate was
7.5% (Table 2). Two hundred ninety-two patients had at least 1 all-cause hospitalization
during follow-up (29% of the cohort with hospitalization data).
Crude clinical outcomes for RDW ranges are shown in Table 2, and Kaplan Meier curves
stratified by RDW ranges are shown in Fig. 1. In univariate analysis, RDW was strongly
associated with adverse outcome, both for all-cause mortality (unadjusted HR 1.09 per 1%
increase in RDW, 95% CI 1.06 to 1.13, P < .001) and for the composite of all-cause
hospitalization or mortality (unadjusted HR 1.10 per 1% increase in RDW, 95% CI 1.07 to
1.13, P < .001). Based on the global chi-square statistic in the final adjusted model, elevated
RDW had the third strongest statistical association with all-cause mortality (Table 3) and the
combined end point of all-cause hospitalization or mortality (Table 4) among the variables
modeled. Notably, RDW was a stronger predictor of mortality than many other well-
validated predictors, including functional class and age. RDW was found to be a significant
independent predictor of all-cause mortality (adjusted HR 1.07 per 1% increase in RDW,
95% CI 1.01 to 1.13, P = .018) and all-cause hospitalization or mortality (adjusted HR 1.05,
95% CI 1.01 to 1.10, P = .025) in supplemental modeling that included adjustment for blood
urea nitrogen.
No significant evidence was found for a violation of the proportional hazards assumption in
the mortality model (P = .32), nor was there significant evidence for a nonlinear effect of
RDW on the mortality outcome (P = .35).
C-statistic Analysis—Results reflecting the evaluation of RDW and other clinical
predictors for the mortality end point using the c-statistic are shown in Table 5. RDW and
estimated glomerular filtration rate alone were found to have the highest c-statistic of any of
the significant predictors determined by multivariable modeling of mortality. The c-statistic
of the final clinical model lacking RDW did not increase significantly when RDW was
added.
UNITE-HF Biomarker Registry
Baseline Characteristics—The UNITE-HF Biomarker registry enrolled a total of 291
patients who had baseline clinical data and blood available for biomarker analysis. In the
current study, results are reported from 235 of these 291 patients who had RDW values
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available from the registry clinical core laboratory. As expected, the baseline characteristics
of these patients differed in a number of ways compared with the unselected study patients
from the STAMINA-HFP registry. UNITE-HF Biomarker patients were younger, more
likely to be male and African American (data not shown). Median RDW in the UNITE-HF
Biomarker cohort was 14.0% (Q1-Q3 13.2-15.3%). Mean age was 59 ± 14 years, 29% were
female, with a mean ejection fraction 32 ± 15%, New York Heart Association functional
class of 2.6 ± 0.9, and estimated glomerular filtration rate of 67 ± 25 mL·min·1.73 m2. The
mean hemoglobin of the UNITE-HF Biomarker cohort was 13.5 ± 1.7 g/dL with 31%
having anemia by World Health Organization criteria.
Association of RDW with Inflammation and Iron Status—The relationship between
RDW and iron studies, inflammatory cytokines, and other heart failure biomarkers are
shown in Tables 6 and 7. These tables show the results of both continuous analyses of
various measures with RDW and descriptive, categorical analyses based on RDW patient
groups. Increasing RDW was associated with a biochemical profile suggestive of impaired
iron mobilization, typical of anemia of chronic disease. As RDW increased, mean
corpuscular volume decreased, suggesting that the increased variability of red cell size in the
highest RDW patients was due to a greater number of small red blood cells (Fig. 2A). The
classical definition of iron deficiency (iron binding saturation <20%) was present in 46% of
patients. Serum iron levels decreased at higher RDW levels, whereas iron binding capacity
remained stable. As a result, iron saturation decreased with increasing RDW (Fig. 2B).
Consistent with a state of chronic inflammation, ferritin levels were normal in all groups
regardless of RDW. Erythropoietin levels increased significantly with increasing RDW. The
results suggested a specific association between the inflammatory cytokines studied and
RDW. IL-6 was significantly elevated in patients with higher RDW (Table 7, Fig. 2C),
whereas tumor necrosis factor-alpha did not correlate with RDW, and IL-1 beta levels were
inversely correlated with RDW values. Results were similar when patients were divided into
RDW groups based on the normal range for this measurement (data not shown).
This report focuses on the subset of UNITE-HF Biomarker registry patients with both RDW
values and data available for analysis of hematological parameters and selected
neurohormones. In the case of iron status and other hematologic indices, patients with
results available were considered to be representative because these values were available in
the great majority of patients in the UNITE-HF Biomarker cohort with RDW. In the case of
various inflammatory cytokines and endothelin-1, results were available in smaller subsets
of the study cohort. Because IL-6 was found to be related to RDW, the 138 patients with this
data were taken as an example group for comparison of baseline characteristics between
patients with and without neurohormonal results in the study cohort. In addition, these
patients were used to investigate the potential impact that differences in baseline
characteristic may have had on the reported associations between RDW and various
neurohormones. IL-6 data were deemed representative of anemic patients in the study cohort
because IL-6 values were available in 68 of the 72 anemic study patients. In contrast, IL-6
results were available in a smaller percentage of nonanemic patients (69 of 162) and there
were a number of differences in baseline characteristics between nonanemic patients with
and without these results (data not shown). However, of the baseline characteristics that
differed between nonanemics with and without IL-6 results, only heart rate was found to be
a significant predictor of values of this cytokine (data not shown). Importantly, RDW was
significantly related to IL-6 (adjusted P < .001) after taking into account heart rate as well as
all other characteristics that differed between nonanemic patients with and without IL-6
values.
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In this study, we confirmed our previous report of RDW as a powerful marker of prognosis
in chronic heart failure. RDW was among the strongest predictors of both mortality and
hospitalization, even after adjustment for a variety of other clinical and laboratory variables.
As evaluated by the chi-square statistic in the final multivariable model, the prognostic
significance of RDW was comparable to other widely accepted risk markers such as ejection
fraction and New York Heart Association class. The adjusted standardized HR for mortality
(per 1 standard deviation of RDW change) in the STAMINA-HFP registry was 1.17 (95%
CI 1.03 to 1.32), which was similar to that seen in the Candesartan in Heart Failure
Assessment of Reduction in Mortality and Morbidity (CHARM) Program (1.12) and the
Duke Databank (1.29).10 C-statistic results also pointed to the importance of RDW relative
to other independent predictors of mortality in our study population. Additionally, the
current study provides the first data evaluating the relationship between RDW and
biomarkers of inflammation and iron metabolism in heart failure. We found that higher
RDW was associated with biochemical evidence of greater inflammation and impaired iron
mobilization, suggesting that elevated RDW may be an integrative measure of several
potentially important pathophysiologic processes in heart failure.
Importance of RDW as a Risk Predictor
Although potential markers of risk are frequently identified using multivariable modeling in
large datasets, often little effort is made to replicate these findings in independent cohorts,
thereby limiting the validity and generalizability of the observation. Elevated RDW has now
been shown to be a robust marker of risk in 3 distinct cohorts of chronic heart failure,
including a large multicenter clinical trial, a single center registry focused on patients
undergoing cardiac catheterization, and a multicenter, unselected ambulatory heart failure
population. Notably, all 3 of these cohorts include patients with both impaired and preserved
ejection fraction, and were thus broadly representative of the epidemiology of chronic heart
failure. The consistency of these findings across multiple independent datasets argues
strongly for the validity of this association with adverse outcomes. In addition to its strong
association with mortality and hospitalization, RDW is routinely available as part of the
automated blood count that is a standard component routine medical care. Thus, RDW may
represent an exception to the adage that “there’s no such thing as a free lunch,” providing
significant prognostic information without adding cost or complexity to current heart failure
management.
Potential Mechanisms
An emerging concept in cardiovascular disease is the role of the erythrocyte as a barometer
of overall cardiovascular health.18 A variety of mechanisms have been posited to explain the
association between anemia and outcomes in heart failure, including inflammatory stress,
nutritional deficiencies, inadequate production of erythropoietin, and the impact of
comorbidities.6,9 Any or all of these mechanisms can result in anemia, and each may also
lead to elevations in RDW. RDW is a quantitative measure of the variability in size of the
circulating erythrocytes (ie, anisocytosis). Classically, RDW is elevated in conditions of
ineffective red cell production (eg, iron deficiency, anemia of chronic disease, B12 or folate
deficiency, and hemoglobinopathies), increased red cell destruction (eg, hemolysis), or after
blood transfusion.
The association of elevated RDW with low hemoglobin, moderately depressed mean
corpuscular volume, high erythropoietin, normal iron binding capacity, and normal ferritin
are all consistent with a state of impaired iron mobilization. This results in inhibition of
erythropoietin-induced erythrocyte maturation, the hallmark of anemia of chronic disease.19
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Although the prevalence of frank iron deficiency in patients with heart failure is
controversial, there is increasing recognition that the ability to mobilize and use existing iron
stores may be impaired even in the setting of adequate total body iron.20-22 This so called
“reticuloendothelial block” is mediated in part by overexpression of hepcidin, a peptide
hormone secreted by the liver which acts as a regulator of human iron metabolism.23 By
decreasing cell surface expression of the iron exporter ferroportin, hepcidin decreases iron
absorption from the intestine and iron release from reticuloendothelial stores. Hepcidin is
upregulated by a number of stimuli, including anemia, hypoxia, and, in particular,
inflammation.24,25 IL-6, which was strongly associated with elevated RDW in our study, is a
powerful inducer of transcription of the hepcidin gene.26 Additionally, inflammatory
cytokines may directly inhibit erythropoietin-induced erythrocyte maturation, which is
reflected by an increase in RDW.27,28 Taken as a whole, our data suggest the hypothesis that
elevations in RDW may reflect a variety of underlying pathologic processes, such as
inflammatory stress and impaired iron metabolism that may directly contribute to disease
progression in heart failure. Given the challenges of assessing these underlying processes in
clinical practice, RDW may provide a widely available, inexpensive “barometer” that
integrates these complex interactions into a single, well-validated prognostic biomarker.
Limitations
Although the sample size of the current study was large, the mean follow-up was relatively
short at 1 year, which limited the number of overall events. As with all analyses of
observational data, our study cannot distinguish causality from association, both with regard
to the link between RDW and outcomes and between RDW, inflammation, and iron
metabolism. Patients in the STAMINA-HFP registry differ from those in the biomarker
cohort in a number of ways that make it difficult to link findings on outcomes and
disordered iron metabolism from 1 registry to the other. Biochemical data on iron
metabolism and inflammatory cytokines were available on only a subset of the UNITE-HF
Biomarker registry patients. Although this bias could have influenced the relationships
observed between these measures and RDW, as an example, modeling results with IL-6 still
indicate a significant relationship between this cytokine and RDW after accounting for
differences observed.
Conclusions
Elevated RDW had a strong, independent association with adverse outcomes in this
unselected, broadly representative cohort of ambulatory heart failure patients. RDW was a
more powerful predictor of outcome than many commonly used predictors, and has the
advantage of already being routinely available as part of the automated complete blood
count. Elevations in RDW appear to reflect a state of increased inflammation and impaired
iron metabolism, findings that suggest the possibility that RDW may provide an integrated
measure of these underlying processes in heart failure. These findings encourage ongoing
research into the relationship between the hematologic system and human heart failure.
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Unadjusted relationship of red cell distribution width to ad verse outcomes. Kaplan Meier
curves for all-cause mortality (A) and hospitalization or mortality (B) by ranges of red cell
distribution width.
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Relationship of red cell distribution width to indices of iron metabolism and inflammation.
Association of ranges of red cell distribution width with mean corpuscular volume (A), total
iron binding capacity (TIBC) saturation (B), and interleukin (IL)-6 (C). Boxes illustrate the
25th, 50th, and 75th percentiles of the distribution. The mean is given by a square, the
median by the horizontal line, and the whiskers extend to the 5th and 95th percentiles.
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Table 1
Baseline Characteristics for the STAMINA-HFP Registry across Ranges of Red Cell Distribution Width
Characteristic All Patients ≤13.4%
RDW Ranges
13.5-15.4% ≥15.5% P
n 1016 265 493 258
RDW (%) 14.7 ± 2.5 12.8 ± 0.5 14.3 ± 0.6 17.5 ± 3.5 <.001
Demographics
 Age (y) 64 ± 14 61 ± 15 64 ± 14 66 ± 14 .003
 Gender (% female) 42 45 43 38 .237
 Race (% Caucasian) 73 78 73 68 .030
Symptoms
 Mean NYHA class 2.2 ± 0.7 2.1 ± 0.7 2.2 ± 0.7 2.5 ± 0.8 <.001
 Class I (%) 15 21 15 11 <.001
 Class II (%) 47 54 48 37
 Class III (%) 35 24 37 45
 Class IV (%) 2 1 1 7
Medical history
 IHD (%) 50 45 49 55 .082
 Hypertension (%) 69 66 70 71 .326
 Atrial
  fibrillation-flutter (%)
31 22 29 42 <.001
 Diabetes (%) 38 30 39 43 .004
 Current smoking (%) 11 11 11 10 .866
 Current alcohol (%) 21 25 21 17 .080
Physical exam
 Edema (%) 34 25 34 43 < 0.001
 Rales (%) 6 6 5 8 .328
 JVD (%) 12 10 12 15 .133
 SBP (mm Hg) 122 ± 21 122 ± 19 123 ± 22 121 ± 20 .351
 DBP (mm Hg) 71 ± 12 71 ± 11 71 ± 12 70 ± 12 .559
 HR (beats/min) 73 ± 12 72 ± 12 73 ± 12 74 ± 12 .320
Current medications
 β-blocker (%) 81 83 80 80 .463
 ACEI or ARB (%) 87 90 87 84 .112
 Digoxin (%) 47 43 48 50 .196
 Loop diuretic (%) 80 72 81 88 <.001
Laboratory data
 Creatinine (mg/dL) 1.4 ± 1.1 1.2 ± 0.9 1.4 ± 1.3 1.6 ± 1.0 .003
 eGFR (mL·min·1.73 m2) 64 ± 26 69 ± 24 64 ± 26 58 ± 27 <.001
 Hemoglobin (g/dL) 13.3 ± 2.1 13.8 ± 1.9 13.4 ± 2.0 12.5 ± 2.1 <.001
 LVEF (%) 35 ± 16 36 ± 16 36 ± 16 33 ± 16 .081
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular
filtration rate; HR, heart rate; IHD, ischemic heart disease; JVD, jugular venous distention; LVEF, left ventricular ejection fraction; NYHA, New
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York Heart Association; RDW, red cell distribution width; SBP, systolic blood pressure; STAMINA-HFP, Study of Anemia in a Heart Failure
Population.
Continuous variables are expressed as means ± standard deviation. P values are from analyses of variance or chi-square tests for differences among
the groups.













ALLEN et al. Page 15
Table 2
Clinical Outcomes for the STAMINA-HFP Registry at 1 Year across Ranges of Red Cell Distribution Width
Outcome All Patients ≤13.4%
RDW Ranges
13.5-15.5% ≥15.5% P
n 1012 264 491 257
All-cause mortality 7.5 (77) 2.5 (8) 6.2 (30) 15 (39) <.001
At least 1 all-cause hospitalization 31 (292) 21 (51) 32 (147) 38 (94) <.001
Death + hospitalization composite 33 (319) 23 (55) 34 (157) 43 (107) <.001
RDW, red cell distribution width; STAMINA-HFP, Study of Anemia in a Heart Failure Population.
Results displayed as percentages with number of events in parenthesis.
P values are from the log-rank test for differences among the groups.
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Table 3
Multivariable Proportional Hazard Regression Analysis of Mortality
Variable Chi-square HR 95% CI
P
Value
RDW (per 1%) 6.1 1.06 1.01-1.12 .013
Hemoglobin
 (per 1 g/dL decrease)
1.9 1.09 0.96-1.23 .173
Age (per 10 y) 0.6 1.09 0.87-1.37 .434
NYHA class at baseline 1.7 1.26 0.89-1.77 .197
Ischemic heart disease <0.1 1.01 0.60-1.69 .976
Hypertension 1.8 1.52 0.83-2.77 .175
LVEF (per 5 units) 12.5 0.84 0.77-0.93 <.001
eGFR (per 10 units) 7.0 0.85 0.75-0.96 .008
SBP (per 5 units) 0.3 1.02 0.95-1.10 .572
DBP (per 5 units) 6.1 0.85 0.74-0.97 .014
Atrial fibrillation
 or flutter
1.6 1.38 0.84-2.27 .210
Edema on exam 2.6 1.51 0.91-2.51 .110
Any diuretic 0.3 0.52 0.06-4.73 .563
Loop diuretic 1.1 2.96 0.40-21.87 .287
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association; RDW, red cell distribution width; SBP, systolic blood pressure.
Chi-squared statistic each with 1 df.
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Table 4
Multivariable Proportional Hazard Regression Analysis of Combined End Point
Variable Chi-square HR 95% CI
P
Value
RDW (per 1%) 9.2 1.06 1.02-1.10 .002
Hemoglobin
 (per 1 g/dL decrease)
2.9 1.05 0.99-1.12 .087
NYHA class at baseline 20.0 1.49 1.25-1.77 <.001
Ischemic heart disease 2.1 1.20 0.94-1.54 .143
Diabetes mellitus 3.4 1.26 0.99-1.60 .064
LVEF (per 5 units) 8.0 0.94 0.90-0.98 .005
eGFR (per 10 units) 12.7 0.91 0.86-0.96 <.001
SBP (per 5 units) 0.3 0.99 0.96-1.02 .596
Atrial fibrillation
 or flutter
1.7 1.19 0.92-1.53 .191
Edema on exam 0.8 1.12 0.87-1.43 .384
Any diuretic 0.2 0.84 0.43-1.65 .621
Loop diuretic 0.3 1.19 0.66-2.15 .569
eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RDW, red cell
distribution width; SBP, systolic blood pressure.
Chi-squared statistic each with 1 df.
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Table 5




c-statistic 95% CI c-statistic 95% CI
Independent predictors
 RDW 0.69 0.63-0.75 NA NA
 eGFR 0.69 0.63-0.75 0.71 0.65-0.77
 DBP 0.66 0.60-0.73 0.72 0.66-0.78
 LVEF 0.62 0.55-0.69 0.68 0.61-0.74
Multivariable models
 Overall clinical model 0.79 0.73 – 0.84 0.79 0.74 – 0.84
Overall clinical model characteristics same as in Table 3.
All abbreviations are the same as in Tables 1 and 3
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